J&J's Ortho-McNeil unit in another diabetes drug accord, this one with Metabolex

23 June 2010

USA-based Metabolex revealed yesterday that it has entered into a global development and license agreement with health care giant Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals subsidiary to further develop and discover compounds for the treatment of type 2 diabetes and other disorders.

Earlier the same day, Ortho-McNeal said it has signed an accord with Sweden's Diamyd, which could cost it as much as $625 million, for rights to the latter's GAD65 antigen-based therapy for the treatment and prevention of type 1 diabetes (The Pharma Letter June 22).

Under the latest agreement, Ortho-McNeil will receive an exclusive worldwide license to develop, manufacture, and commercialize several Metabolex programs that are currently at the preclinical stage.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK